{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": 9.832631, "regularMarketPrice": 10.5, "exchange": "NCM", "shortName": "POINT Biopharma Global Inc.", "longName": "POINT Biopharma Global Inc.", "messageBoardId": "finmb_656424964", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "bookValue": 4.464, "fiftyDayAverage": 7.6479, "fiftyDayAverageChange": 2.8521, "fiftyDayAverageChangePercent": 0.37292588, "twoHundredDayAverage": 7.785975, "twoHundredDayAverageChange": 2.714025, "twoHundredDayAverageChangePercent": 0.3485787, "marketCap": 1109776512, "forwardPE": -11.931818, "priceToBook": 2.3521504, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "tradeable": false, "cryptoTradeable": false, "earningsTimestamp": 1684150200, "earningsTimestampStart": 1691670600, "earningsTimestampEnd": 1692016200, "trailingAnnualDividendRate": 0.0, "trailingPE": 8.823529, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 1.19, "epsForward": -0.88, "epsCurrentYear": -0.97, "priceEpsCurrentYear": -10.824742, "sharesOutstanding": 105683000, "firstTradeDateMilliseconds": 1594215000000, "priceHint": 2, "preMarketChange": 0.05000019, "preMarketChangePercent": 0.4761923, "preMarketTime": 1684224797, "preMarketPrice": 10.55, "regularMarketChange": 0.9399996, "regularMarketTime": 1684180805, "regularMarketDayHigh": 11.06, "regularMarketDayRange": "9.74 - 11.06", "regularMarketDayLow": 9.74, "regularMarketVolume": 1975474, "regularMarketPreviousClose": 9.56, "bid": 0.0, "ask": 0.0, "bidSize": 8, "askSize": 11, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 9.87, "averageDailyVolume3Month": 671635, "averageDailyVolume10Day": 889980, "fiftyTwoWeekLowChange": 4.95, "fiftyTwoWeekLowChangePercent": 0.89189184, "fiftyTwoWeekRange": "5.55 - 11.13", "fiftyTwoWeekHighChange": -0.6300001, "fiftyTwoWeekHighChangePercent": -0.056603782, "fiftyTwoWeekLow": 5.55, "fiftyTwoWeekHigh": 11.13, "marketState": "PRE", "displayName": "POINT Biopharma Global", "symbol": "PNT"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "4850 West 78th Street", "city": "Indianapolis", "state": "IN", "zip": "46268", "country": "United States", "phone": "647 812 2417", "website": "https://www.pointbiopharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.", "fullTimeEmployees": 129, "companyOfficers": [{"maxAge": 1, "name": "Mr. Allan Charles Silber", "age": 72, "title": "Exec. Chairman", "yearBorn": 1950, "fiscalYear": 2022, "totalPay": {"raw": 1024801, "fmt": "1.02M", "longFmt": "1,024,801"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 20019, "fmt": "20.02k", "longFmt": "20,019"}}, {"maxAge": 1, "name": "Dr. Joe A. McCann Ph.D.", "age": 44, "title": "CEO & Director", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": {"raw": 1063662, "fmt": "1.06M", "longFmt": "1,063,662"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Neil E. Fleshner FRCSC, M.D., M.PH", "age": 58, "title": "Chief Medical Officer & Director", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 318485, "fmt": "318.49k", "longFmt": "318,485"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Jessica D. Jensen M.P.H., MPH", "age": 41, "title": "Exec. VP of Clinical Devel.", "yearBorn": 1981, "fiscalYear": 2022, "totalPay": {"raw": 816171, "fmt": "816.17k", "longFmt": "816,171"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 40177, "fmt": "40.18k", "longFmt": "40,177"}}, {"maxAge": 1, "name": "Mr. Bill  Demers B.B.A., F.C.A., FCPA", "age": 63, "title": "CFO & Corp. Sec.", "yearBorn": 1959, "fiscalYear": 2020, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Justyna  Kelly M.Sc.", "age": 37, "title": "Chief Operating Officer", "yearBorn": 1985, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ari  Shomair", "title": "VP of Corp. Affairs & Chief of Staff", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Myra Rosario Herle Ph.D., R.Ph.", "title": "Exec. VP of Regulatory Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Matthew P. Vincent J.D., Ph.D.", "title": "Sr. VP of Bus. Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chris  Horvath", "title": "Exec. VP of Commercial", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 5, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 6, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}